Advertisement
Advertisement

CRMD

CRMD logo

CorMedix Inc.

7.50
USD
Sponsored
-0.01
-0.13%
May 13, 16:00 UTC -4
Closed
exchange

Pre-Market

7.55

+0.05
+0.73%

CRMD Earnings Reports

Positive Surprise Ratio

CRMD beat 25 of 41 last estimates.

61%

Next Report

Today BMO
Date of Next Report
May 14, 2026
Estimate for Q1 26 (Revenue/ EPS)
$107.12M
/
$0.37
Implied change from Q4 25 (Revenue/ EPS)
-16.71%
/
+105.56%
Implied change from Q1 25 (Revenue/ EPS)
+174.09%
/
+23.33%

CorMedix Inc. earnings per share and revenue

On Mar 05, 2026, CRMD reported earnings of 0.18 USD per share (EPS) for Q4 25, missing the estimate of 0.83 USD, resulting in a -78.38% surprise. Revenue reached 128.62 million, compared to an expected 129.56 million, with a -0.73% difference. The market reacted with a +1.60% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 3 analysts forecast an EPS of 0.37 USD, with revenue projected to reach 107.12 million USD, implying an increase of 105.56% EPS, and decrease of -16.71% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
logo
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
logo
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
logo
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
logo
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
logo
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
logo
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-
Actual
-$0.05
Surprise
-
logo
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
logo
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
logo
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
For Q4 2025, CorMedix Inc. reported EPS of $0.18, missing estimates by -78.38%, and revenue of $128.62M, -0.73% below expectations.
The stock price moved up 1.6%, changed from $7.51 before the earnings release to $7.63 the day after.
The next earning report is scheduled for May 14, 2026.
Based on 3 analysts, CorMedix Inc. is expected to report EPS of $0.37 and revenue of $107.12M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement